|
1
|
Han B, Zheng R, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2022. J Natl Cancer Cent. 4:47–53. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Song W, Gao P, Guan X, Wang B, Zhang
L, Yao Y, Guo Y, Wang Y, Jiang S and Sun S: Global, regional, and
national burden of breast, cervical, uterine, and ovarian cancer
and their risk factors among women from 1990 to 2021, and
projections to 2050: Findings from the global burden of disease
study 2021. BMC Cancer. 25:3302025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Freitas AJA, Causin RL, Varuzza MB,
Hidalgo Filho CMT, Silva VDD, Souza CP and Marques MMC: Molecular
biomarkers predict pathological complete response of neoadjuvant
chemotherapy in breast cancer patients: Review. Cancers (Basel).
13:54772021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dubsky P, Pinker K, Cardoso F, Montagna G,
Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G,
Gentilini O, et al: Breast conservation and axillary management
after primary systemic therapy in patients with early-stage breast
cancer: the Lucerne toolbox. Lancet Oncol. 22:e18–e28. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hurvitz SA, Martin M, Symmans WF, Jung KH,
Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D,
Wildiers H, et al: Neoadjuvant trastuzumab, pertuzumab, and
chemotherapy versus trastuzumab emtansine plus pertuzumab in
patients with HER2-positive breast cancer (KRISTINE): A randomised,
open-label, multicentre, phase 3 trial. Lancet Oncol. 19:115–126.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim HJ, Dominici L, Rosenberg SM, Zheng Y,
Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, et al:
Surgical treatment after neoadjuvant systemic therapy in young
women with breast cancer: Results from a prospective cohort study.
Ann Surg. 276:173–179. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
von Minckwitz G, Blohmer JU, Costa SD,
Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J,
Huober J, et al: Response-guided neoadjuvant chemotherapy for
breast cancer. J Clin Oncol. 31:3623–3630. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conforti F, Pala L, Sala I, Oriecuia C, De
Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E,
et al: Evaluation of pathological complete response as surrogate
endpoint in neoadjuvant randomised clinical trials of early stage
breast cancer: Systematic review and meta-analysis. BMJ.
375:e0663812021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Azambuja E, Holmes AP, Piccart-Gebhart
M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I,
Smith I, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): Survival outcomes of a randomised,
open-label, multicentre, phase 3 trial and their association with
pathological complete response. Lancet Oncol. 15:1137–1146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng Q, Yan H, He Y, Wang J, Zhang N, Huo
L, Liu Y, Wang L, Xu L and Fan Z: An ultrasound-based nomogram for
predicting axillary node pathologic complete response after
neoadjuvant chemotherapy in breast cancer: Modeling and external
validation. Cancer. 130:1513–1523. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Değerli E, Şentürk Öztaş N, Alkan G, Bedir
Ş, Derin S, Valıkhanova N, Saraç B, Kacar E, Demirci NS, Demirelli
HF and Turna H: Relationship between pathological response and
molecular subtypes in locally advanced breast cancer patients
receiving neoadjuvant chemotherapy. J Chemother. 35:29–38. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang T, Liu Y and Tian T: Predicting
pathological complete response after neoadjuvant chemotherapy in
breast cancer by clinicopathological indicators and ultrasound
parameters using a nomogram. Sci Rep. 14:163482024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sikov WM, Berry DA, Perou CM, Singh B,
Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER,
et al: Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense
doxorubicin and cyclophosphamide on pathologic complete response
rates in stage II to III triple-negative breast cancer: CALGB 40603
(Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu
J, Lee JE and Lee SK: Nomogram for accurate prediction of breast
and axillary pathologic response after neoadjuvant chemotherapy in
node positive patients with breast cancer. Ann Surg Treat Res.
96:169–176. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maimaitiaili A, Li Y, Chai N, Liu Z, Ling
R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, et al: A nomogram for
predicting pathologic node negativity after neoadjuvant
chemotherapy in breast cancer patients: A nationwide, multicenter
retrospective cohort study (CSBrS-012). Front Oncol.
14:13263852024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anthracycline-containing and
taxane-containing chemotherapy for early-stage operable breast
cancer: A patient-level meta-analysis of 100 000 women from 86
randomised trials. Lancet. 401:1277–1292. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nižnanský Ľ, Osinová D, Kuruc R, Hengerics
Szabó A, Szórádová A, Masár M and Nižnanská Ž: Natural taxanes:
From plant composition to human pharmacology and toxicity. Int J
Mol Sci. 23:156192022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gradishar WJ, Moran MS, Abraham J,
Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J,
Burstein HJ, et al: Breast cancer, version 3.2024, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
22:331–357. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Symons R, Heath F, Duggan J, Bui KT, Byun
L, Friedlander M and Lee YC: Rates of paclitaxel hypersensitivity
reactions using a modified Markman's infusion protocol as primary
prophylaxis. Support Care Cancer. 32:2922024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bi Z, Chen P, Liu YB, Zhao T, Sun X, Song
XR and Wang YS: Efficacy and safety analysis of paclitaxel,
docetaxel and liposomal paclitaxel after neoadjuvant therapy in
breast cancer. Breast Cancer Res Treat. 184:397–405. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dieci MV, Griguolo G, Bottosso M,
Tsvetkova V, Giorgi CA, Vernaci G, Michieletto S, Angelini S,
Marchet A, Tasca G, et al: Impact of estrogen receptor levels on
outcome in non-metastatic triple negative breast cancer patients
treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer.
7:1012021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giuliano AE, Edge SB and Hortobagyi GN:
Eighth Edition of the AJCC cancer staging manual: Breast cancer.
Ann Surg Oncol. 25:1783–1785. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kerr AJ, Dodwell D, McGale P, Holt F,
Duane F, Mannu G, Darby SC and Taylor CW: Adjuvant and neoadjuvant
breast cancer treatments: A systematic review of their effects on
mortality. Cancer Treat Rev. 105:1023752022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spring LM, Fell G, Arfe A, Sharma C,
Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ,
et al: Pathologic complete response after neoadjuvant chemotherapy
and impact on breast cancer recurrence and survival: A
comprehensive Meta-analysis. Clin Cancer Res. 26:2838–2848. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ortmann O, Blohmer JU, Sibert NT, Brucker
S, Janni W, Wöckel A, Scharl A, Dieng S, Ferencz J, Inwald EC, et
al: Current clinical practice and outcome of neoadjuvant
chemotherapy for early breast cancer: Analysis of individual data
from 94,638 patients treated in 55 breast cancer centers. J Cancer
Res Clin Oncol. 149:1195–1209. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guan D, Jie Q, Wu Y, Xu Y, Hong W and Meng
X: Real-world data on breast pathologic complete response and
disease-free survival after neoadjuvant chemotherapy for hormone
receptor-positive, human epidermal growth factor
receptor-2-negative breast cancer: A multicenter, retrospective
study in China. World J Surg Oncol. 20:3262022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Villegas SL, Nekljudova V, Pfarr N, Engel
J, Untch M, Schrodi S, Holms F, Ulmer HU, Fasching PA, Weber KE, et
al: Therapy response and prognosis of patients with early breast
cancer with low positivity for hormone receptors-An analysis of
2765 patients from neoadjuvant clinical trials. Eur J Cancer.
148:159–170. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loibl S, O'Shaughnessy J, Untch M, Sikov
WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag
D, et al: Addition of the PARP inhibitor veliparib plus carboplatin
or carboplatin alone to standard neoadjuvant chemotherapy in
triple-negative breast cancer (BrighTNess): A randomised, phase 3
trial. Lancet Oncol. 19:497–509. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai
L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, et al:
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic
complete response in women with early-stage breast cancer: An
analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.
JAMA Oncol. 6:676–684. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early Triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dou H, Li F, Wang Y, Chen X, Yu P, Jia S,
Ba Y, Luo D, Gao T, Li Z and Xiao M: Estrogen
receptor-negative/progesterone receptor-positive breast cancer has
distinct characteristics and pathologic complete response rate
after neoadjuvant chemotherapy. Diagn Pathol. 19:52024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ahn S, Woo JW, Lee K and Park SY: HER2
status in breast cancer: Changes in guidelines and complicating
factors for interpretation. J Pathol Transl Med. 54:34–44. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baumgartner A, Tausch C, Hosch S,
Papassotiropoulos B, Varga Z, Rageth C and Baege A:
Ultrasound-based prediction of pathologic response to neoadjuvant
chemotherapy in breast cancer patients. Breast. 39:19–23. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Denkert C, Loibl S, Müller BM, Eidtmann H,
Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, et
al: Ki67 levels as predictive and prognostic parameters in
pretherapeutic breast cancer core biopsies: A translational
investigation in the neoadjuvant GeparTrio trial. Ann Oncol.
24:2786–2793. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim SY, Cho N, Choi Y, Lee SH, Ha SM, Kim
ES, Chang JM and Moon WK: Factors affecting pathologic complete
response following neoadjuvant chemotherapy in breast cancer:
Development and validation of a predictive nomogram. Radiology.
299:290–300. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Chen X, Zhu Q, Chen R, Xu L, Li S,
Shi X, Xu H, Xu Y, Zhang W, et al: Retrospective comparisons of
nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant
regimens for breast cancer. Nanomedicine (Lond). 16:391–400. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu X, Ye C, Wang X, Cai R, Yang J, Yu X,
Zhou Y, Shen L, Zhu Y and Liu X: The efficacy and toxicity of
neoadjuvant chemotherapy regimens of epirubicin plus
cyclophosphamide followed by docetaxel or paclitaxel in female
breast cancer patients. Cancer Manag Res. 13:1517–1527. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jivani A and Shinde RK: A comprehensive
review of taxane treatment in breast cancer: Clinical perspectives
and toxicity profiles. Cureus. 16:e592662024.PubMed/NCBI
|
|
43
|
Zhang W, Wang Y, He J, Xu Y, Chen R, Wan
X, Shi W, Huang X, Xu L, Wang J and Zha X: Efficacy comparisons of
solvent-based paclitaxel, liposomal paclitaxel, nanoparticle
albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic
treatment in breast cancer. Nanomedicine. 54:1027072023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang W, Xu Y, Shi X, Huang X, Chen R, Xu
H, Shi W, Wan X, Wang Y, He J, et al: Nanoparticle albumin-bound
paclitaxel is superior to liposomal paclitaxel in the neoadjuvant
treatment of breast cancer. Nanomedicine (Lond). 17:683–694. 2022.
View Article : Google Scholar : PubMed/NCBI
|
